Synlogic Overview
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
SYBX
- Investments
-
2
- Share Price
-
$0.98
- (As of Wednesday Closing)
Synlogic General Information
Description
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
Contact Information
Website
www.synlogictx.comCorporate Office
- PO Box 30
- Winchester, MA 01890
- United States
Corporate Office
- PO Box 30
- Winchester, MA 01890
- United States
Synlogic Stock Performance
As of 18-Nov-2026, Synlogic’s stock price is $0.98. Its current market cap is $12M with 12.2M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.98 | $1.10 | $0.54 - $1.73 | $12M | 12.2M | 18.4K | $0.42 |
Synlogic Financials Summary
As of 30-Sep-2026, Synlogic has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 536 | (2,488) | (3,014) | 20,163 |
| Revenue | 0 | 0 | 8 | 3,371 |
| EBITDA | (2,737) | (1,700) | (24,432) | (61,769) |
| Net Income | (2,226) | (1,005) | (23,359) | (61,273) |
| Total Assets | 11,849 | 15,447 | 19,826 | 75,550 |
| Total Debt | 0 | 0 | 0 | 17,275 |
Synlogic Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Synlogic Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Synlogic Comparisons
Industry
Financing
Details
Synlogic Competitors (103)
One of Synlogic’s 103 competitors is BioAtla, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioAtla | Formerly VC-backed | San Diego, CA | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| AbCellera Biologics | Formerly VC-backed | Vancouver, Canada | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Clearside Biomedical | Formerly VC-backed | Alpharetta, GA |
Synlogic Patents
Synlogic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024298173-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Pending | 26-Jul-2023 | ||
| EP-4750891-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Pending | 26-Jul-2023 | ||
| US-20260226448-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Pending | 26-Jul-2023 | ||
| WO-2025024642-A1 | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | Inactive | 26-Jul-2023 | ||
| JP-2026528174-A | Recombinant bacteria engineered to treat diseases related to methionine metabolism and their use. | Pending | 26-Jul-2023 | C12N15/70 |
Synlogic Signals
Synlogic Acquisitions (2)
Synlogic’s most recent deal was a Reverse Merger with Caldera Therapeutics. The deal was made on 29-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Caldera Therapeutics | 29-Jul-2026 | Reverse Merger | Drug Discovery | ||
| Mirna Therapeutics | 28-Aug-2017 | Merger/Acquisition | Biotechnology |
Synlogic ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Synlogic Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Synlogic Ibdco | Cambridge, MA | 2017 |
Synlogic FAQs
-
Where is Synlogic headquartered?
Synlogic is headquartered in Winchester, MA.
-
What is the size of Synlogic?
Synlogic has 87 total employees.
-
What industry is Synlogic in?
Synlogic’s primary industry is Drug Discovery.
-
Is Synlogic a private or public company?
Synlogic is a Public company.
-
What is Synlogic’s stock symbol?
The ticker symbol for Synlogic is SYBX.
-
What is the current stock price of Synlogic?
As of 18-Nov-2026 the stock price of Synlogic is $0.98.
-
What is the current market cap of Synlogic?
The current market capitalization of Synlogic is $12M.
-
Who are Synlogic’s competitors?
BioAtla, Vir Biotechnology, AbCellera Biologics, Aclaris Therapeutics, and Clearside Biomedical are some of the 103 competitors of Synlogic.
-
What is Synlogic’s annual earnings per share (EPS)?
Synlogic’s EPS for 12 months was $0.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process